TAG:
precision medicine
Astorg Makes Billion-Dollar Bet on Microbiology Testing
Thermo Fisher Scientific has agreed to sell its microbiology business to European private equity firm Astorg in a deal valued at $1.075 billion. The transaction, announced in April, includes $1.025 billion in cash and a $50 million seller note. It is expected to …
Digital Pathology’s Next Wave May Be in Precision Medicine
We’ve noted before that the adoption of digital pathology has not been as swift or strong as originally predicted. Many factors contribute to that concern. This topic came up in a recent interview The Dark Report conducted with Imoge…
Top Stories in 2025 Played Out in Courts, Capitol Hill
CEO SUMMARY: The biggest story of the year for clinical laboratories came in a huge court victory, as a federal judge vacated the FDA’s final rule on laboratory developed tests. Labs breathed a sigh of relief after the court decision, as the FDA rule had promised to incr…
December 29, 2025, Intelligence: Late-Breaking Lab News
The US Department of Veterans Affairs (VA) is expanding its use of precision medicine through a new multi-year contract with Baylor Genetics to provide pharmacogenomic (PGx) and germline genetic testing to veterans across the VA’s nationwide healthcare system. The agreement includes P…
December 8, 2025, Intelligence: Late-Breaking Lab News
For the next 46 months, a Georgia fraudster will stay behind bars after pleading guilty to charges he violated the Anti-Kickback Statute by arranging for medically unnecessary genetic tests. A judge sentenced Patrick C. Moore, Jr. on Dec. 2. Moore was also ordered to pay $7.2 million in…
November 17, 2025, Intelligence: Late-Breaking Lab News
Dealmaking continues in the in vitro diagnostics (IVD) industry as AI-driven genomics and private equity reshape the market for a data-first future. On Nov. 4, Qiagen said it will acquire Parse Biosciences for $280 million to expand its reach into single-cell sequencing, levera…
Deal Offers Signals about the Future of Digital Pathology
THE DIGITAL PATHOLOGY MARKET IS AT AN INFLECTION POINT, AND TEMPUS’ RECENT $81.25 MILLION ACQUISITION OF PAIGE underscores both the challenges and opportunities ahead. While the pandemic temporarily accelerated digital pathology adoption, with vendors raising large su…
Profitable Collaboration with Pharma Companies
CEO SUMMARY: Drug discovery efforts by pharmaceutical companies often need a boost from anatomic pathology practices and clinical laboratories. Forward-thinking lab leaders and pathologists can take advantage of their data and expertise to partner with pharma, setting the …
Workers Use AI More than Lab Leaders Think
CEO SUMMARY: In part one of an analysis about the state of AI in clinical laboratories, The Dark Report explores how frontline workers, especially younger ones, are using AI tools like ChatGPT far more than lab leaders. Recent reports elsewhere in the business world show e…
State of Whole Genome Sequencing of Newborns
CEO SUMMARY: Genetic medicine continues to support advances in precision medicine (or personalized medicine, if you prefer). This is true in pediatrics, where several statewide pilot programs—each involving tens of thousands of newborns—are publishing studies that demonstrate how exom…
CURRENT ISSUE
Volume XXXIII, No. 11 – September 2026
In the September 2026 briefing, The Dark Report digs into a CMS proposal to cut payments for CPT code 88305, potentially based on flawed thinking. Other coverage includes the evolving role of mass spectrometry in clinical labs, payer obstacles to blood-based biomarker tests for Alzheimer’s disease, and how young pathologists can get business skill help.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.